/

RIGL

Rigel Pharmaceuticals, Inc.Closed

47.14−1.67 −3.42%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 47.14 0.00%

Open

48.70

Prev close

48.81

Day range

47.0548.87

52-week range

24.9552.24

Volume

134.00K0.47×

Mkt cap

880.57M

P/E ttm

2.79

Fwd P/E

9.54

EPS ttm

16.88

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−9.76%

Price Chart

Yahoo Finance · delayed

RIGLOct 13, 2026O 48.70H 48.87L 47.04C 47.14−1.67 (−3.42%)Vol 134.00K

SMA 5045.91
SMA 20036.72

1Y change +67.28% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RIGL Rigel Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.23%
1 month: −0.21%
3 months: +14.50%
6 months: +50.18%
Year to date: +10.06%
1 year: +75.70%

Valuation & ownership

Market cap: 880.57M
Enterprise value: 825.19M
P/E (ttm): 2.79
Forward P/E: 9.54
PEG ratio: —
Price / book: 2.07
Price / sales (ttm): 3.18
EV / EBITDA: 9.20
EPS (ttm): 16.88
EPS (forward): 4.94
Beta (5y monthly): 1.19
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 18.68M
Float: 14.84M
Short % of float: 15.69%
Short ratio (days): 12.24
Held by insiders: 3.35%
Held by institutions: 89.32%
Avg volume (3m): 282.16K
50-day average: 45.72
200-day average: 36.70
52-week change: +75.70%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 49.6
vs 50-day SMA: +2.67%
vs 200-day SMA: +28.39%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.88%
Realised vol (20d, ann.): 34.2%
From 52-week high: −9.76%
From 52-week low: +88.94%

ANR

Analyst Consensus

5 analysts

Consensus

—

Mean target

63.00

+33.64% implied

Low 43.00Median 55.00High 85.00

Recommendation trend

Now3 / 2 / 0
1m ago3 / 2 / 0
2m ago

DES

About Rigel Pharmaceuticals, Inc.

Yahoo Finance profile

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 172
Headquarters: South San Francisco, CA, United States
Website: rigel.com

SEAS

Seasonality · RIGL

2007–2026 · monthly returns

Strongest month Dec +18.06%Weakest month Oct −7.55%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-18.6	-0.3	-22.2	6.9	5.5	28.3	-5.9	25.5	4.3	-2.1			+10.1%
2025	28.7	6.5	-22.0	8.7	-1.8	-2.4	12.4	84.5	-27.1	11.5	59.9	-15.2	+154.6%
2024	-19.3	29.9	-2.6	-29.1	-6.7	-16.1	28.7	27.0	20.4	-15.8	102.6	-39.1	+16.0%
2023	9.3	-7.9	-12.6	-14.4	23.9	-7.9	7.0	-17.4	-5.3	-25.0	40.7	27.2	−3.3%
2022	-3.4	-2.0	19.1	-21.1	-23.3	-37.6	5.3	19.3	-16.9	-38.1	-8.2	123.9	−43.4%
2021	4.0	14.0	-17.6	8.8	0.0	16.7	-7.8	-5.0	-4.5	-7.4	-20.5	-0.7	−24.3%
2020	5.6	-6.2	-26.4	14.7	9.5	-6.6	25.7	8.3	-3.6	3.3	22.2	15.5	+63.6%
2019	-6.1	1.4	17.4	-13.2	-4.5	22.5	-12.6	-25.9	10.7	9.6	9.3	-4.5	−7.0%
2018	3.1	-6.0	-5.9	2.0	-10.0	-12.9	-0.4	20.9	-5.9	-10.6	-1.4	-18.7	−40.7%
2017	-12.6	17.8	35.1	-9.7	-23.4	19.2	-13.2	7.6	-0.4	47.6	10.9	-6.7	+63.0%
2016	-9.2	-17.5	-8.4	36.1	-8.8	-13.6	2.7	47.2	8.9	-29.2	0.0	-8.5	−21.5%
2015	-8.8	44.4	19.4	19.3	-18.1	-8.0	-7.2	0.7	-17.7	2.8	29.1	-7.6	+33.5%
2014	6.3	13.5	12.8	-17.5	2.8	10.3	-9.9	-20.5	-25.4	2.1	8.1	6.1	−20.4%
2013	0.9	2.4	1.2	-29.6	-3.5	-27.7	14.1	-17.3	13.7	-14.0	-13.6	7.1	−56.2%
2012	23.8	2.4	-19.5	-4.0	-3.9	25.2	17.6	-14.8	9.9	-13.0	-6.8	-21.7	−17.6%
2011	-10.6	3.9	1.7	28.1	-8.9	10.5	-5.2	-9.3	-6.6	6.7	-2.9	3.5	+4.8%
2010	-13.7	-8.0	5.6	-2.5	-16.1	10.4	12.5	-3.3	7.4	-1.2	-4.0	-5.6	−20.8%
2009	-12.6	-24.9	17.0	8.1	25.6	45.3	-31.2	-15.5	16.3	-21.8	18.1	25.6	+18.9%
2008	8.4	-28.0	-5.9	20.6	3.7	-2.9	12.3	-7.0	-1.3	-62.7	-14.8	7.8	−68.5%
2007	-4.4	-7.8	3.7	-2.4	-8.1	-8.5	-10.7	15.1	2.9	11.7	-32.0	254.6	+113.9%

INSD

Insider Activity · RIGL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

72.6K shares

Sells, 6 months

5K shares

Net shares

+67.6K

Net change in insider shares

+12.10%

Date	Insider	Transaction	Shares	Value
Sep 1, 2026	Schorno Dean LChief Financial Officer	Conversion of Exercise of derivative security at price 12.70 - 24.20 per share.	4.6K	$99.93K
Jul 7, 2026	Hannah Alison L.Officer	Stock Award(Grant) at price 0.00 per share.	24.4K	—
Jun 21, 2026	Ali-Jackson KamilDirector	Sale at price 35.00 per share.	2.5K	$87.50K
May 31, 2026	Schorno Dean LChief Financial Officer	Conversion of Exercise of derivative security at price 12.70 - 18.70 per share.	3.4K	$50.14K
May 25, 2026	Ali-Jackson KamilDirector	Sale at price 29.17 per share.	2.5K	$72.92K
May 14, 2026	Moos Walter HDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
May 14, 2026	Miller Michael PatrickDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
May 14, 2026	Frohlich Mark WDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
May 14, 2026	Lapointe Anthony GreggDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
May 14, 2026	Wasman JaneDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
May 14, 2026	Hannah Alison L.Director	Stock Award(Grant) at price 0.00 per share.	5.8K	—
May 14, 2026	Ali-Jackson KamilDirector	Stock Award(Grant) at price 0.00 per share.	5.8K	—
Feb 19, 2026	Moos Walter HDirector	Sale at price 36.36 per share.	4K	$145.44K
Feb 19, 2026	Moos Walter HDirector	Conversion of Exercise of derivative security at price 24.00 per share.	4K	$96.00K
Feb 16, 2026	Rodriguez Raul RChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	53.9K	—
Feb 16, 2026	Schorno Dean LChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	20.6K	—
Feb 16, 2026	Furey Raymond JGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	19.5K	—
Feb 16, 2026	Santos David AOfficer	Stock Award(Grant) at price 0.00 per share.	19.4K	—
Feb 16, 2026	Rojkjaer LisaOfficer	Stock Award(Grant) at price 0.00 per share.	18.9K	—
Jan 25, 2026	Rodriguez Raul RChief Executive Officer	Conversion of Exercise of derivative security at price 27.40 per share.	80K	$2.19M

13F

Investors Holding RIGL

latest 13F filings of 29 followed managers

Investors holding RIGL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$5.7M	0.01%	145.85K	−57%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RIGL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RIGL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Rigel Pharmaceuticals, Inc.

Seasonality · RIGL

Insider Activity · RIGL

Congress Trades · RIGL

Investors Holding RIGL

Investors Holding RIGL

Congress Trades · RIGL

Insider Activity · RIGL

Seasonality · RIGL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Rigel Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News